Oncology

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.

Findings, presented at SABCS 2024, support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with “good-risk” DCIS who opt to skip RT.

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.